Clodronate kinetics and bioavailability

Gerald J. Yakatan, Wesley J. Poynor, Robert L. Talbert, Benjamin F. Floyd, Candice L. Slough, Robert S. Ampulski, James J. Benedict

Research output: Contribution to journalArticle

103 Scopus citations


Carbon 13-labeled clodronate disodium was given to healthy adult men by intravenous infusion and orally in a crossover design. Serum and urine levels were determined as a function of time by isotope-ratio mass spectrometry. Clodronate disodium (Cl2MDP) is primarily excreted unchanged by the kidney; more than 80% of the intravenous dose was recovered within 48 hr. The serum concentration-time curve over the first 8 hr after intravenous dosing appears biexponential with the disposition phase having a harmonic mean half-life (t 1 2) of 2 hr. The mean serum clearance was found to be 1.4 ml min-1 kg-1 and the apparent volume of distribution was approximately 25% of body weight. Simulations and computer fitting of the cumulative urinary excretion and urinary excretion rates based on the biexponential serum decay curve demonstrated the presence of a slow disposition component with a t 1 2 of 12.8 hr. Thus, the disposition kinetics of Cl2MDP appear to be triexponential, although the slowest component is not of major significance after a single dose and could not be verified because of a lack of serum data after 8 hr. Cl2MDP is poorly absorbed with an absolute bioavailability of only 1 % to 2%.

Original languageEnglish (US)
Pages (from-to)402-410
Number of pages9
JournalClinical Pharmacology and Therapeutics
Issue number3
Publication statusPublished - Mar 1982


ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Yakatan, G. J., Poynor, W. J., Talbert, R. L., Floyd, B. F., Slough, C. L., Ampulski, R. S., & Benedict, J. J. (1982). Clodronate kinetics and bioavailability. Clinical Pharmacology and Therapeutics, 31(3), 402-410.